Showing results (191-200 of 392) with videos related to

Sort By:
Pageof 40
Haematologica|October 30, 2020
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, et al.
Haematologica|January 13, 2018
Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogoninClaudia Dürr, Bola S Hanna, Angela Schulz, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Haematologica|October 8, 2008
Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genesKatrina Vanura, Trang Le, Harald Esterbauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S Davids, Bryone J Kuss, Peter Hillmen, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Leukemia|November 16, 2019
Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cellsAnnika Scheffold, Ali H Baig, Zhiyang Chen, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
British Journal of Haematology|February 19, 2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN studyStephan Stilgenbauer, Francesc Bosch, Osman Ilhan, et al.
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.
Pageof 40